Rapport Therapeutics RAPP
$23.16 −$0.43 (-1.82%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $23.16 0.00%
Open$23.23
Prev close$23.59
Day range$23.00 – $23.83
Volume437.7K
Market cap$1.37B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$44.09M-47.0% YoY
Net profit-$40.24M-49.4% YoY
Diluted EPS-$0.84-18.3% YoY
Free cash flow-$41.63M-136.6% YoY
Operating cash flow-$41.63M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-838.1%
Net margin-752.4%
Return on equity-33.3%
Return on assets-31.5%
Return on invested capital-36.3%
Current ratio20.07
Liabilities / assets6.5%
Cash & investments$395.03M
Total debt$7.07M
Net cash (debt)$387.96M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $20.00M | $0.00 | $0.00 |
| Operating Expense | $44.09M | $60.81M | $44.22M | $125.10M | $38.51M |
| Selling and Admin Expenses | $9.77M | $9.39M | $11.50M | $30.31M | $8.25M |
| -General & Admin Expense | $9.77M | $9.39M | $11.50M | $30.31M | $8.25M |
| Research & Development | $34.32M | $51.41M | $32.72M | $94.79M | $30.26M |
| Operating Profit | -$44.09M | -$60.81M | -$24.22M | -$125.10M | -$38.51M |
| Net Non-Operating Interest Income (Expense) | $3.85M | $4.19M | $4.36M | $13.62M | $4.75M |
| Non-Operating Interest Income | $3.85M | $4.19M | $4.36M | $13.62M | $4.75M |
| Pretax Profit | -$40.24M | -$56.62M | -$19.86M | -$111.48M | -$33.76M |
| Net Profit | -$40.24M | -$56.62M | -$19.86M | -$111.48M | -$33.76M |
| Profit from Continuing Operations | -$40.24M | -$56.62M | -$19.86M | -$111.48M | -$33.76M |
| Net Income to Parent Company | -$40.24M | -$56.62M | -$19.86M | -$111.48M | -$33.76M |
| Net Income to Common Stockholders | -$40.24M | -$56.62M | -$19.86M | -$111.48M | -$33.76M |
| Basic EPS | -$0.84 | -$1.19 | -$0.42 | -$2.86 | -$0.72 |
| Diluted EPS | -$0.84 | -$1.19 | -$0.42 | -$2.86 | -$0.72 |
| Total Revenue as Reported | – | $0.00 | $20.00M | – | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $418.56M | $458.98M | $497.60M | $512.43M | $512.43M |
| Total Current Assets | $407.38M | $446.86M | $484.70M | $498.56M | $498.56M |
| Cash and Cash Equivalents & Short-Term Investments | $395.03M | $436.08M | $476.78M | $490.54M | $490.54M |
| -Cash and Cash Equivalents | $74.75M | $63.61M | $78.06M | $52.65M | $52.65M |
| -Short Term Investments | $320.28M | $372.47M | $398.73M | $437.89M | $437.89M |
| Receivables | $171,000.00 | $293,000.00 | $58,000.00 | – | – |
| -Accounts Receivable | $171,000.00 | $293,000.00 | $58,000.00 | – | – |
| Restricted Cash | $105,000.00 | $105,000.00 | $105,000.00 | $105,000.00 | $105,000.00 |
| Other Current Assets | $12.08M | $10.38M | $7.75M | $7.92M | $7.92M |
| Total Non-Current Assets | $11.18M | $12.13M | $12.90M | $13.87M | $13.87M |
| Net PPE | $10.08M | $11.07M | $11.85M | $12.89M | $12.89M |
| -Gross PPE | $12.20M | $13.21M | $13.78M | $14.87M | $14.87M |
| -Accumulated Depreciation | -$2.12M | -$2.14M | -$1.93M | -$1.98M | -$1.98M |
| Other Non-Current Assets | $1.10M | $1.06M | $1.06M | $985,000.00 | $985,000.00 |
| Total Liabilities | $27.37M | $36.06M | $26.09M | $27.78M | $27.78M |
| Total Current Liabilities | $20.30M | $28.42M | $17.90M | $19.05M | $19.05M |
| Payables | $1.72M | $2.80M | $6.56M | $4.19M | $4.19M |
| -Accounts Payable | $1.72M | $2.80M | $6.56M | $4.19M | $4.19M |
| Current Accrued Expenses | $10.61M | $18.91M | $5.65M | $4.98M | $4.98M |
| Short-Term Debt and Capital Lease Obligation | $2.33M | $2.47M | $2.62M | $2.76M | $2.76M |
| -Current Capital Lease Obligation | $2.33M | $2.47M | $2.62M | $2.76M | $2.76M |
| Total Non-Current Liabilities | $7.07M | $7.63M | $8.19M | $8.73M | $8.73M |
| Long Term Debt and Capital Lease Obligation | $7.07M | $7.63M | $8.19M | $8.73M | $8.73M |
| -Long Term Capital Lease Obligation | $7.07M | $7.63M | $8.19M | $8.73M | $8.73M |
| Total Equity | $391.19M | $422.93M | $471.51M | $484.65M | $484.65M |
| Stockholders' Equity | $391.19M | $422.93M | $471.51M | $484.65M | $484.65M |
| Capital Stock | $48,000.00 | $48,000.00 | $48,000.00 | $48,000.00 | $48,000.00 |
| -Common Stock | $48,000.00 | $48,000.00 | $48,000.00 | $48,000.00 | $48,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $745.19M | $735.85M | $727.05M | $719.29M | $719.29M |
| Retained Earnings | -$351.94M | -$311.70M | -$255.09M | -$235.23M | -$235.23M |
| Gains/Losses Not Affecting Retained Earnings | -$2.12M | -$1.27M | -$505,000.00 | $546,000.00 | $546,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$41.63M | -$41.46M | -$13.06M | -$87.47M | -$24.70M |
| Net cash flow from continuing operations | -$41.63M | -$41.46M | -$13.06M | -$87.47M | -$24.70M |
| Net Income from Continuing Operations | -$40.24M | -$56.62M | -$19.86M | -$111.48M | -$33.76M |
| Gain/Loss from Continuing Operations | -$15,000.00 | -$1,000.00 | $153,000.00 | – | – |
| Depreciation & Depletion & Amortization | $198,000.00 | $212,000.00 | $227,000.00 | $1.02M | $265,000.00 |
| Other Non-Cash Items | $608,000.00 | $595,000.00 | $582,000.00 | $2.03M | $571,000.00 |
| Change in Working Capital | -$9.47M | $6.81M | -$765,000.00 | $3.50M | $3.61M |
| -Change in Receivables | $122,000.00 | -$235,000.00 | -$58,000.00 | – | – |
| -Change in Prepaid Assets | -$855,000.00 | -$3.16M | $814,000.00 | -$3.60M | -$987,000.00 |
| -Change in Payables and Accrued Expense | -$8.02M | $10.90M | -$1.19M | $8.38M | $4.86M |
| -Change in Other Current Assets | -$2,000.00 | $0.00 | $346,000.00 | -$791,000.00 | $119,000.00 |
| -Change in Other Current Liabilities | -$716,000.00 | -$698,000.00 | -$681,000.00 | -$491,000.00 | -$389,000.00 |
| Net cash flow from investing | $51.06M | $25.60M | $37.94M | -$187.47M | -$174.32M |
| Net Cash Flow from Continuing Investing Activities | $51.06M | $25.60M | $37.94M | -$187.47M | -$174.32M |
| Net PPE Purchase and Sale | $208,000.00 | $115,000.00 | -$86,000.00 | -$616,000.00 | -$169,000.00 |
| Net Investment Purchase and Sale | $50.86M | $25.49M | $38.03M | -$186.86M | -$174.16M |
| Financing Cash Flow | $1.71M | $1.41M | $531,000.00 | $270.79M | $311,000.00 |
| Net Cash Flow from Continuing Financing Activities | $1.71M | $1.41M | $531,000.00 | $270.79M | $311,000.00 |
| Net Common Stock Issuance | $0.00 | $0.00 | -$5,000.00 | $269.44M | -$395,000.00 |
| Proceeds from Stock Option Exercised | $1.71M | $1.59M | $809,000.00 | $1.35M | $706,000.00 |
| Net Other Financing Charges | $1,000.00 | -$181,000.00 | -$273,000.00 | – | – |
| Ending Cash Balance | $74.86M | $63.72M | $78.16M | $52.75M | $52.75M |
| Net Change in Cash | $11.14M | -$14.44M | $25.41M | -$4.16M | -$198.71M |
| Beginning Cash Balance | $63.72M | $78.16M | $52.75M | $56.91M | $251.46M |
| Free Cash Flow | -$41.63M | -$41.53M | -$13.15M | -$88.09M | -$24.87M |
| Net Preferred Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on RAPP.
Sign in to join the discussion.